Zetia Cost in Kentucky 2026: Prices, Medicaid, and the Cheapest Way to Pay

What Ezetimibe Actually Does, and Why Kentuckians Need It

Ezetimibe lowers LDL-cholesterol by blocking the Niemann-Pick C1-Like 1 (NPC1L1) transporter in the small intestine, cutting dietary and biliary cholesterol absorption by roughly 50% [1]. It does not inhibit cholesterol synthesis, so it works through a completely different mechanism than statins. That difference makes it a natural add-on when a statin alone leaves LDL above goal.

Cardiovascular disease kills more Kentuckians than any other cause. According to the CDC, Kentucky's age-adjusted heart disease death rate consistently ranks among the five highest in the nation [2]. High LDL is one of the most modifiable risk factors, and combination therapy with a statin plus ezetimibe is now endorsed by the 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease [3].

The IMPROVE-IT trial (N=18,144) published in the New England Journal of Medicine in 2015 remains the foundational evidence for ezetimibe's clinical value. Over a median follow-up of 6 years, adding ezetimibe 10 mg to simvastatin 40 mg reduced the composite cardiovascular endpoint (cardiovascular death, major coronary event, or nonfatal stroke) by 6.4% relative risk reduction compared with simvastatin alone (32.7% vs. 34.7%, P<0.001) [4]. That reduction was modest in absolute terms, about 2 percentage points, but meaningful across a large, high-risk population. The American College of Cardiology cited IMPROVE-IT in formally upgrading ezetimibe's recommendation class [3].

The FDA first approved ezetimibe (branded Zetia) in 2002 for hypercholesterolemia as monotherapy and in combination with statins [5]. Multiple generic manufacturers entered the market in 2012 after patent expiration, and that competition is the single biggest reason cash-pay prices in Kentucky are now close to $15 per month.

The Real Zetia Price Picture in Kentucky for 2026

The gap between brand-name and generic pricing in Kentucky is enormous. The Merck list price for branded Zetia sits near $380 per month in 2026. Generic ezetimibe 10 mg tablets average about $15 per month at Kentucky retail pharmacies when purchased with a discount card, a more than 95% reduction [6].

Pricing varies by pharmacy. GoodRx, NeedyMeds, and the RxSaver programs each negotiate contracts with pharmacy benefit managers independently, so the price for a 30-tablet supply of generic ezetimibe can range from roughly $10 at a Walmart or Costco pharmacy to $22 at a regional independent pharmacy without a discount card. Asking the pharmacy to run the GoodRx coupon instead of insurance is one of the fastest ways to capture savings, since many insured patients pay higher copays than the cash-pay generic price [7].

A 90-day supply through mail-order programs (including some Medicare Part D preferred mail pharmacies) may bring the per-tablet cost even lower. The 2022 Inflation Reduction Act's drug pricing provisions do not yet directly cap ezetimibe prices under Medicare, but Part D plan formulary negotiations have kept generic ezetimibe well below the brand price on most plans [8].

Does Kentucky Medicaid Cover Zetia?

Kentucky Medicaid (administered through managed care organizations under Kentucky HEALTH) does not list branded Zetia on its Preferred Drug List (PDL) for hyperlipidemia. Generic ezetimibe coverage depends on the specific managed care plan, Anthem Kentucky Medicaid, Aetna Better Health of Kentucky, Humana Healthy Horizons, Molina Healthcare, and UnitedHealthcare Community Plan each maintain separate formularies [9].

As of early 2025, generic ezetimibe is not a preferred agent on most Kentucky Medicaid MCO formularies. Statins, specifically atorvastatin and simvastatin, are preferred first-line agents. A prescriber who believes a Medicaid member needs ezetimibe can submit a prior authorization (PA) request documenting a trial of at least one preferred statin at maximum tolerated dose and an inadequate LDL response. The ACC/AHA guideline language stating that "for patients with clinical ASCVD in whom the recommended intensity of statin therapy cannot be used or the response is inadequate, ezetimibe should be considered" is commonly cited in PA appeals [3].

If a PA is denied, the cash-pay generic price of roughly $15 per month is low enough that some patients find paying out of pocket simpler than navigating the PA process [10]. Clinicians should document LDL values before and after the statin trial to support any appeal.

Is Compounded Ezetimibe Legal in Kentucky?

Compounded ezetimibe prepared by a 503A pharmacy is legal in Kentucky. Section 503A of the Federal Food, Drug, and Cosmetic Act governs traditional compounding pharmacies that compound drugs for individual patients based on a valid prescription from a licensed practitioner [11]. Kentucky-licensed 503A pharmacies may compound ezetimibe as long as a patient-specific prescription exists, the pharmacy holds an active Kentucky Board of Pharmacy license, and the compounded product is not essentially a copy of a commercially available drug without a documented clinical difference.

The "essentially a copy" restriction is the key legal nuance. Because commercially available ezetimibe 10 mg tablets are widely available and inexpensive, a 503A pharmacist must have a clinically justifiable reason to compound, for example, a patient who requires a different dose, a dye-free formulation due to documented allergy, or a liquid suspension for dysphagia [12]. A prescriber's note documenting the clinical necessity provides the legal basis for the compound.

Some telehealth practices pair patients with 503A compounding partners who offer ezetimibe at little or no cost as part of a cardiovascular wellness program. That pricing model is feasible because compounding raw ezetimibe API (active pharmaceutical ingredient) costs far less than manufacturing a commercial tablet at scale. The FDA has not placed ezetimibe on its list of drugs that may not be compounded under 503A [11].

Kentucky Board of Pharmacy Rule 201 KAR 2:175 governs compounding standards within the state, requiring pharmacies to follow USP Chapter 795 for non-sterile preparations [13]. Patients ordering compounded ezetimibe from out-of-state compounding pharmacies should confirm those pharmacies hold a Kentucky nonresident pharmacy license.

Which Insurance Plans Cover Zetia in Kentucky?

Coverage varies substantially by plan type. Here is a practical breakdown.

Medicare Part D. Most Part D plans in Kentucky cover generic ezetimibe, typically at the Tier 1 or Tier 2 level with copays ranging from $0 to $15 per month for preferred generics. Branded Zetia, when covered at all, sits on Tier 3 or higher with copays exceeding $45 per month [14]. Patients should use Medicare's Plan Finder tool to compare specific plan formularies before enrollment.

Commercial insurance. Large employers using national pharmacy benefit managers (Express Scripts, CVS Caremark, OptumRx) typically cover generic ezetimibe at Tier 1 or Tier 2. Branded Zetia without a PA is usually Tier 3 or non-preferred, with copays of $40 to $80 per month. Merck's Zetia savings card can reduce branded out-of-pocket costs for commercially insured patients who qualify, the card does not apply to government insurance programs [15].

Kentucky state employee health plans. The Kentucky Employees' Health Plan (KEHP) uses a formulary that covers generic ezetimibe at generic copay rates, typically $10 to $20 per month for a 30-day supply [9].

Uninsured or underinsured patients. The generic cash-pay price of roughly $15 per month is usually lower than any insured copay tier for branded Zetia, making discount cards the practical first step [6].

The ACC/AHA 2022 guideline update on nonstatin therapies notes that "cost-effectiveness of ezetimibe therapy is favorable at current generic prices," explicitly referencing the sub-$20 per month price point as a factor supporting its use [16].

Can I Get a Zetia Prescription via Telehealth in Kentucky?

Yes. Kentucky allows telehealth prescribing of ezetimibe. The Kentucky telehealth law (KRS 211.332) permits licensed Kentucky practitioners to evaluate and prescribe medications via synchronous audio-video encounters [17]. Ezetimibe is not a controlled substance, so it faces none of the additional restrictions that apply to Schedule II through V medications.

A standard telehealth visit for ezetimibe typically involves a review of recent lipid panel results, a brief medical history, and documentation of current medications. Most telehealth platforms can generate an electronic prescription sent directly to the patient's preferred Kentucky pharmacy or to a partner compounding pharmacy. The American Telemedicine Association notes that non-controlled chronic disease medications like lipid-lowering agents are among the safest and most appropriate categories for telehealth prescribing [18].

Patients with no recent lipid panel may be asked to obtain one before a prescription is issued, since a 2018 ACC expert consensus decision pathway specifies that treatment decisions for LDL lowering should be based on fasting or non-fasting LDL-C values obtained at least twice [19]. Some telehealth services partner with Quest Diagnostics or LabCorp to order labs directly, completing the entire process without an in-person visit.

The Cheapest Way to Get Ezetimibe in Kentucky: A Ranked Approach

Cost varies by pathway. Ranked from lowest to highest typical monthly out-of-pocket cost for a Kentucky resident in 2026:

1. 503A compounded ezetimibe through a qualifying program: $0/month. Available through select telehealth cardiovascular programs that absorb compounding costs. Requires a valid prescription and documented clinical need for the compound.

2. Generic ezetimibe with a GoodRx or RxSaver discount card: approximately $10 to $15/month. Works at most major Kentucky pharmacy chains including Kroger Pharmacy, CVS, Walgreens, Walmart, and independent pharmacies. No insurance required.

3. Generic ezetimibe through Medicare Part D preferred mail-order: approximately $0 to $10/month. Available to Medicare beneficiaries whose plan includes a preferred mail-order benefit.

4. Generic ezetimibe under commercial insurance Tier 1 or 2: approximately $10 to $20/month. Most large Kentucky employer plans.

5. Branded Zetia with Merck savings card under commercial insurance: approximately $25 to $50/month. The Merck savings card (available at merck.com) reduces commercial copays but is not valid for Medicare, Medicaid, or other government programs [15].

6. Branded Zetia without savings assistance: $380/month list price. Essentially the price only paid by patients without insurance or discount programs who are prescribed brand-name specifically.

The FDA's Orange Book confirms therapeutic equivalence between branded Zetia and all AB-rated generic ezetimibe products, meaning pharmacists in Kentucky may substitute generics unless a prescriber writes "Dispense as Written" [20].

Ezetimibe Dosing, Side Effects, and Drug Interactions

The standard dose is ezetimibe 10 mg orally once daily, taken with or without food, at any time of day [5]. No dose adjustment is required for mild to moderate renal impairment, and no hepatic dose adjustment is needed in mild hepatic impairment. Ezetimibe is not recommended in patients with moderate to severe hepatic impairment because of unpredictable pharmacokinetics [5].

Common side effects are mild. In clinical trials, the most frequently reported adverse events were upper respiratory infection (4.3% vs. 3.8% placebo), diarrhea (4.1% vs. 3.7%), arthralgia (3.0% vs. 2.2%), and sinusitis (2.8% vs. 2.5%) [5]. Myopathy risk, the primary safety concern with statins, is not meaningfully elevated by ezetimibe monotherapy. When ezetimibe is combined with a statin, myopathy risk reflects the statin dose rather than ezetimibe itself [4].

The most clinically relevant drug interaction is with bile acid sequestrants (cholestyramine, colesevelam). Taking ezetimibe and a bile acid sequestrant simultaneously reduces ezetimibe absorption; dosing ezetimibe at least 2 hours before or 4 hours after the sequestrant preserves efficacy [5]. Cyclosporine increases ezetimibe exposure roughly 12-fold and requires careful monitoring in transplant patients [21].

A 2020 Cochrane systematic review of ezetimibe for the prevention of cardiovascular disease (29 trials, N=22,000+) found no increase in cancer risk, hepatotoxicity, or myopathy rates compared with placebo, supporting its long-term safety profile [22].

Monitoring LDL After Starting Ezetimibe

The ACC/AHA guideline recommends checking a fasting lipid panel 4 to 12 weeks after initiating or changing lipid-lowering therapy, then every 3 to 12 months as clinically indicated [3]. Ezetimibe typically lowers LDL-C by 13 to 20% as monotherapy and by an additional 13 to 20% when added to a statin [1].

In patients with heterozygous familial hypercholesterolemia (HeFH), where statin monotherapy rarely achieves LDL targets, ezetimibe plus high-intensity statin is standard second-line therapy before escalating to PCSK9 inhibitors. The Familial Hypercholesterolaemia Studies Collaboration (FHSC) registry data, involving more than 42,000 patients across 56 countries, showed that ezetimibe use approximately doubled the proportion of HeFH patients reaching LDL <100 mg/dL compared with statin alone [23].

Telehealth prescribers in Kentucky typically arrange follow-up lipid panels through partnered labs and review results remotely, adjusting therapy without requiring the patient to travel. That workflow aligns with the KRS 211.332 standard, which permits ongoing chronic disease management via telehealth as long as the clinical encounter meets standard-of-care documentation requirements [17].

How the Merck Savings Card Works (and Its Limits)

Merck offers a branded Zetia savings card for commercially insured patients that reduces monthly out-of-pocket costs to as low as $25 per month, depending on plan design [15]. Enrollment requires visiting the Merck patient assistance portal, verifying commercial insurance status, and downloading or printing the card.

The card cannot be used by patients enrolled in Medicare Part A or B, Medicare Part D, Medicaid, TRICARE, or any other federal or state healthcare program [15]. Using the card in those circumstances constitutes a federal anti-kickback violation. Kentucky pharmacists are required to reject the card for government-insured patients and should counsel those patients on the generic cash-pay alternative instead.

For uninsured patients who cannot afford even generic prices, Merck's patient assistance program (PAP) provides Zetia at no cost to qualifying low-income patients [15]. Income thresholds change annually; patients should check the current eligibility criteria directly with Merck or through NeedyMeds.org.

Given that generic ezetimibe costs roughly $15 per month in Kentucky without any manufacturer assistance, the savings card provides the greatest marginal benefit only to commercially insured patients whose plan does not carry generic ezetimibe at a preferred tier, a situation that is increasingly rare as generics become universal.